Which tumor markers should be tested for the evaluation of various cancers?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Which Tumor Markers Should Be Tested?

The tumor markers you should test depend entirely on the specific cancer type and clinical context—there is no universal panel for "cancer screening." Testing should be guided by established cancer diagnosis or high clinical suspicion, not used for general screening in asymptomatic individuals.

Key Principle: Cancer-Specific Testing

Tumor markers are not recommended for general cancer screening in asymptomatic populations. Their primary utility is in monitoring known cancers, assessing prognosis, and guiding treatment decisions 1, 2.

Recommended Tumor Markers by Cancer Type

Colorectal Cancer

  • CEA (Carcinoembryonic Antigen) is the only strongly recommended marker 1:

    • Preoperatively: Order if it assists staging and surgical planning
    • Postoperative surveillance: Every 3 months for stage II-III disease for at least 3 years (only if patient is candidate for surgery/chemotherapy)
    • Monitoring metastatic disease: Every 1-3 months during active treatment
    • Not for screening: CEA should never be used to screen for colorectal cancer 1

  • CA 19-9: Insufficient data to recommend for colorectal cancer management 1

Pancreatic Cancer

  • CA 19-9 has limited utility 1:
    • Not for screening or determining operability
    • May measure every 1-3 months in patients with locally advanced/metastatic disease receiving active therapy
    • Rising levels suggest progression but require confirmation with imaging—cannot be used alone

Breast Cancer

  • ER (Estrogen Receptor) and PR (Progesterone Receptor): Mandatory on all newly diagnosed invasive breast cancers to predict endocrine therapy response 3
  • HER2: Mandatory for selecting anti-HER2 therapy (trastuzumab, pertuzumab, etc.) 3
  • CA 15-3 or CA 27.29: Insufficient evidence for routine use in monitoring 4
  • CEA: Not recommended for routine breast cancer management 4

Liver Cancer (Hepatocellular Carcinoma)

  • AFP (Alpha-fetoprotein) 5:
    • Use with abdominal ultrasound for early detection in high-risk patients (chronic hepatitis B/C, cirrhosis)
    • AFP >200 µg/L with typical hypervascular lesions >2 cm suggests HCC
    • Posttreatment monitoring as adjunct to imaging

Germ Cell Tumors (Testicular/Ovarian)

  • AFP and hCG (Human Chorionic Gonadotropin): Essential for diagnosis, prognosis, and monitoring 6, 2
  • LDH (Lactate Dehydrogenase): For prognostic evaluation 2

Ovarian Cancer

  • CA 125: For monitoring therapy response in diagnosed patients 6, 2
  • Not sufficiently sensitive/specific for general screening

Prostate Cancer

  • PSA (Prostate-Specific Antigen): Widely used but value in screening remains controversial with unclear mortality benefit 6, 2

Markers NOT Recommended

The following have insufficient evidence for routine clinical use 1, 5:

  • p53, ras, thymidine synthase, DPD, TP (colorectal cancer)
  • 18q LOH, DCC protein, MSI (colorectal cancer prognosis)
  • CEA (gastric cancer)
  • SCC antigen (cervical cancer)
  • Bladder cancer urine markers (cannot replace cystoscopy/cytology)

Critical Caveats

  1. False elevations occur: Chemotherapy (especially oxaliplatin) can falsely elevate CEA—wait until treatment completion before surveillance 1

  2. Confirmation required: Rising tumor markers alone do not justify treatment changes—always confirm with imaging or clinical findings 1, 5

  3. Timing matters: Spurious early rises may occur in first 4-6 weeks of new therapy 1

  4. Benign conditions: Many markers can be elevated in non-malignant diseases, limiting specificity 7

  5. Method variability: Significant between-method variation exists (CV 5-25% depending on marker)—use same laboratory/method for serial monitoring 8

Emerging Context

Molecular markers are increasingly important 9: Gene panel testing (next-generation sequencing) and companion diagnostics for targeted therapies are now standard for treatment selection, but traditional serum tumor markers remain the workhorses for monitoring established cancers 9, 7.

References

2
Research

Evidence for the clinical use of tumour markers.

Annals of clinical biochemistry, 2004

6
Research

Tumor markers in clinical practice: a review focusing on common solid cancers.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2013

7
Research

Clinical usefulness of circulating tumor markers.

Clinical chemistry and laboratory medicine, 2023

8
Research

Standardization of tumor markers - priorities identified through external quality assessment.

Scandinavian journal of clinical and laboratory investigation. Supplementum, 2016

Related Questions

What baseline serum tumor markers should be ordered at diagnosis, and how should they be used to monitor treatment response and detect recurrence?
After initiating chemotherapy, how long does it typically take for tumor marker levels to begin decreasing?
Which laboratory tests are recommended for the workup and management of breast cancer?
What are tumor markers, including their types, history, mechanisms of action, clinical uses, specific characteristics, and recent updates?
What are the hematologic (blood) tests for oncology (cancer) diagnosis?
What is the recommended antibiotic regimen and duration for a hemodynamically stable pediatric patient with Enterobacter cloacae urosepsis who has been afebrile for ≥48 hours and has adequate source control?
What is the appropriate testing method for alpha‑gal (galactose‑α‑1,3‑galactose) syndrome?
Can tamsulosin be used in a patient with an estimated glomerular filtration rate of 29 mL/min/1.73 m²?
How should I manage a mild autoimmune disease flare that occurred after receiving the influenza vaccine?
What is mean arterial pressure, how is it calculated, and what are the normal target ranges and initial management for abnormal values?
Is magnesium 400 mg twice daily appropriate for a patient with an estimated glomerular filtration rate of 61 mL/min?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.